Table 2. Indicator, attributes, questions and scoring.
| Attribute | Questions | Scoring Options | Score |
|---|---|---|---|
| Incidence Rate | |||
| IR1: Reported Rate | Average reported TB case notification data for 2017–2020 | Range 1: >700 | 15 |
| Range 2: 500–699 | 13 | ||
| Range 3: 250–499 | 11 | ||
| Range 4: <250 | 0 | ||
| Specific TB hotspot(s) reported within study target area | Yes | 5 | |
| No | 0 | ||
| IR2: Accuracy | Estimated population of study target area provided | Yes | 5 |
| No | 0 | ||
| Number of years of data provided | Point for each year (max 4) | 1–4 | |
| Provided additional prevalence data | Yes | 5 | |
| No | 0 | ||
| IR3: Granularity | Description of study target area | Informative | Informative |
| Characterization of study target area | Urban | 5 | |
| Peri-Urban | 4 | ||
| Suburban | 3 | ||
| Rural | 2 | ||
| Other | 1 | ||
| Characterization of TB hotspots | Urban | 5 | |
| Peri-Urban | 4 | ||
| Suburban | 3 | ||
| Rural | 2 | ||
| Other | 1 | ||
| IR4: Justification | Types of evidence of TB frequency provided | TB Notification Report | 1 |
| TB Treatment Register | 1 | ||
| TB Laboratory Register | 1 | ||
| Clinic Facility Report | 1 | ||
| Other | Based on SME | ||
| Provided evidence of TB frequency (URL or attachment) | Yes | 5 | |
| No | 0 | ||
| Types of evidence of TB incidence provided | Scientific Publication | 1 | |
| Survey | 1 | ||
| Other | Based on SME | ||
| Provided evidence of TB incidence (URL or attachment) | Yes | 5 | |
| No | 0 | ||
| Capacity | |||
| CP1: Study Area Capacity | Characterization of study target area | Urban | 5 |
| Peri-Urban | 4 | ||
| Suburban | 3 | ||
| Rural | 2 | ||
| Other | Based on SME | ||
| CP2: TPT Policy | National TPT Guidelines and Updates | Completed | 5 |
| Not Completed | 0 | ||
| CP3: Lab Capacity | Experience with blood samples | Yes | 4 |
| Experience with sputum samples | Yes | 4 | |
| Experience with international shipping of lab samples | Yes | 4 | |
| Experience with QuantiFERON-TB processing | Yes | 4 | |
| Experience working with a nearby lab for sample testing | Yes | 4 | |
| Timeliness | |||
| TL1: Timeliness | Number of business days to questionnaire completion | < = 5 days to complete | 5 |
| 6–10 days to complete | 3 | ||
| >10 days to complete | 2 | ||
| Completeness | |||
| CO1: Complete | Number of answers completed | All answered | 5 |
| < = 3 questions left blank | 3 | ||
| >3 questions left blank | 1 | ||
| TOTAL SCORE | 100 | ||
TB, tuberculosis; TPT, Tuberculosis Preventive Treatment.